Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5133- ART/DHA,    Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells
- in-vitro, GBM, U87MG - in-vitro, GBM, U251
AntiTum↑, tumCV↓, Apoptosis↓, MMP↓, Cyt‑c↑, Casp9↑, CHOP/DDIT3↑, GRP78/BiP↑, eIF2α↑, Casp12↑, ER Stress↑, TumAuto↑, ROS↑,
5132- ART/DHA,    Dihydroartemisinin Exerts Its Anticancer Activity through Depleting Cellular Iron via Transferrin Receptor-1
- in-vitro, Liver, HepG2 - in-vitro, BC, MCF7
Iron↓, TfR1/CD71↓, ROS↑,
5131- ART/DHA,    Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells
- in-vitro, NSCLC, ASTC-a-1
Apoptosis↑, MMP↓, Casp3↑, TumCP↓,
5130- ART/DHA,    Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway
- in-vitro, Bladder, T24/HTB-9
tumCV↓, eff↓, Apoptosis↑, Casp3↑, ROS↑, Cyt‑c↑, MMP↓, Bcl-2↓, BAX↑, MOMP↑, TumCG↓,
4991- ART/DHA,  doxoR,    Dihydroartemisinin alleviates doxorubicin-induced cardiotoxicity and ferroptosis by activating Nrf2 and regulating autophagy
- in-vivo, Nor, H9c2
*cardioP↑, *ROS↓, *Ferroptosis↓, *NRF2↑, Keap1↓,
4992- ART/DHA,    Dihydroartemisinin Increases the Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via the Nrf2/HO-1 Anti-Oxidant Signaling Pathway
- in-vitro, AML, HL-60
Apoptosis↑, Diff↑, ROS↓, HO-1↓, NRF2∅,
4993- ART/DHA,    Dihydroartemisinin inhibits galectin-1–induced ferroptosis resistance and peritoneal metastasis of gastric cancer via the Nrf2–HO-1 pathway
- vitro+vivo, GC, NA
Ferroptosis↑, NRF2↓, HO-1↓, PI3K↓, Akt↓, TumMeta↓,
2323- ART/DHA,    Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
PKM2↓, lactateProd↓, GlucoseCon↓, cycD1/CCND1↓, Bcl-2↓, MMP2↓, VEGF↓, Casp3↑, cl‑PARP↑, BAX↑, DNAdam↑, ROS↑,
2322- ART/DHA,    Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis
- in-vitro, Melanoma, NA
TumCP↓, PKM2↓, LDHA↓, Glycolysis↓,
2321- ART/DHA,    Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, EC9706
Pyro↑, PKM2↓, Casp8↑, Casp3↑, Warburg↓, TumCCA↑, Apoptosis↑,
2320- ART/DHA,    Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
- in-vitro, AML, K562 - in-vitro, Liver, HepG2
Glycolysis↓, GlucoseCon↓, lactateProd↓, GLUT1↓, PKM2↓, ECAR↓, LDHA↓, cMyc↓, other↝,
2324- ART/DHA,    Research Progress of Warburg Effect in Hepatocellular Carcinoma
- Review, Var, NA
PKM2↓, GLUT1↓, Glycolysis↓, Akt↓, mTOR↓, Hif1a↓, HK2↓, LDH↓, NF-kB↓,
2569- ART/DHA,    A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
- Human, Nor, NA
*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,
2570- ART/DHA,    Discovery, mechanisms of action and combination therapy of artemisinin
- Review, Nor, NA
*BioAv↓, *Half-Life↓, *toxicity↓, *ROS↑, GSH↓, selectivity↑,
2575- ART/DHA,  docx,    Artemisia santolinifolia-Mediated Chemosensitization via Activation of Distinct Cell Death Modes and Suppression of STAT3/Survivin-Signaling Pathways in NSCLC
- in-vitro, Lung, H23
ChemoSen↑, GPx4↓, ROS↑, Ferroptosis↑, eff↑,
2571- ART/DHA,    Cancer combination therapies with artemisinin-type drugs
- Review, Var, NA
AntiTum↑, ChemoSen↑, hepatoP↝,
2572- ART/DHA,  SRF,    Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
- in-vitro, AML, NA
CHOP/DDIT3↑, Mcl-1↓, ChemoSen↑, selectivity↑,
2573- ART/DHA,    Cell death mechanisms induced by synergistic effects of halofuginone and artemisinin in colorectal cancer cells
- in-vitro, CRC, HCT116
eff↑,
2574- ART/DHA,    Artemisinin: A Promising Adjunct for Cancer Therapy
- Review, Var, NA
selectivity↑, eff↑,
2576- ART/DHA,  AL,    The Synergistic Anticancer Effect of Artesunate Combined with Allicin in Osteosarcoma Cell Line in Vitro and in Vivo
- in-vitro, OS, MG63 - in-vivo, NA, NA
eff↑, tumCV↓, Casp3↑, Casp9↑, Apoptosis↑, TumCG↓,
2577- ART/DHA,    Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
- Review, Var, NA
eff↑, TumCCA↑, BioAv↑, eff↑, ChemoSen↑,
2578- ART/DHA,  RES,    Synergic effects of artemisinin and resveratrol in cancer cells
- in-vitro, Liver, HepG2 - in-vitro, Cerv, HeLa
Dose↝, TumCMig↓, Apoptosis↑, necrosis↑, ROS↑, eff↑,
2580- ART/DHA,  VitC,    Effects of Antioxidants and Pro-oxidants on Cytotoxicity of Dihydroartemisinin to Molt-4 Human Leukemia Cells
- in-vitro, AML, NA
eff↓, other↝, ROS↑, eff↓, eff↓,
2581- ART/DHA,  PB,    Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells
- in-vitro, AML, NA
eff↑, selectivity↑,
2582- ART/DHA,  5-ALA,    Mechanistic Investigation of the Specific Anticancer Property of Artemisinin and Its Combination with Aminolevulinic Acid for Enhanced Anticolorectal Cancer Activity
- in-vivo, CRC, HCT116 - in-vitro, CRC, HCT116
eff↑, ROS↑, selectivity↑, TumCG↓, toxicity↓,
2461- ASA,    Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
- Review, NA, NA
AntiAg↑, COX1↓, eff↑,
5403- ASA,    Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
- Trial, CRC, NA
Risk↓, other↝,
5416- ASA,    Cancer Incidence and Mortality With Aspirin in Older Adults
- Trial, Var, NA
Risk∅, OS∅,
5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, COX1↓, TXA2↓, AntiAg↑, EMT↓, TumCMig↓, TumCI↓, AMPK↑, cMyc↓, PGE2↓, Dose↑, RadioS↑, PD-L1↓, E-cadherin↑, EMT↓, Slug↓, Vim↓, Twist↓, MMP2↓, MMP9↓, other↑,
5414- ASA,    Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
- Review, Var, NA
Risk↓, *toxicity↓, other↑, *COX1↓, TumCP↓, DNArepair↑, ChemoSen↑, other↓,
5413- ASA,    Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin
- Trial, Nor, NA
*cardioP↑, *other↝, *COX1↓, *TXA2↓,
5412- ASA,    Clinical Pharmacology of Aspirin
- Review, NA, NA
*COX1↓, *COX2/PTGS2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,
5411- ASA,    Mechanistic Insights into a Classic Wonder Drug—Aspirin
- Review, Var, NA
*COX2/PTGS2↓, *COX1↓, *Inflam↓, *cardioP↑, Risk↓,
5410- ASA,    Low-Dose Aspirin and the Prevention of Colorectal Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
- Study, CRC, NA
Risk↓, Dose↝, Risk↓,
5408- ASA,    An aspirin a day keeps cancer at bay
- Review, Var, NA
TumMeta↓, TXA2↓, *AntiAg↑, COX1↓,
5400- ASA,    Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
- Review, Nor, NA
Risk↓, *Inflam↓, *COX1↓, *AntiAg↑, *Half-Life↓, *BioAv↑,
5401- ASA,    Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15R-prostaglandins that inhibit platelet aggregation
- Review, Nor, NA
*AntiAg↑, *COX1↓,
5399- ASA,    Effect of Aspirin on Cancer Incidence and Mortality in Older Adults
- Trial, Nor, NA
Risk↝, Risk↑, Risk∅, Risk↑, other↝,
5409- ASA,    Role of aspirin in cancer prevention
- Review, Var, NA
Imm↑, *Inflam↓, *AntiAg↑, *GutMicro↑, eff↑, TumMeta↓, angioG↓, Risk↓, Risk↓,
5402- ASA,    Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity
- Review, Var, NA
COX1↓, TumMeta↓, *Half-Life↓, *COX2/PTGS2↓, *TXA2↓,
5404- ASA,    Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway
- Study, CRC, NA
Risk↓, other↝, Dose↝, Risk↓, other↓, other↝, KRAS↓, other↓, other↓,
5405- ASA,    Exploring Aspirin’s Potential in Cancer Prevention: A Comprehensive Review of the Current Evidence
- Review, Var, NA
Risk↓, COX1↓, PGE2↓, Inflam↓, *AntiAg↓, PI3K↓, Akt↓, Risk↓,
5406- ASA,    Adjuvant aspirin therapy and colorectal cancer survival
- Trial, CRC, NA
Dose↝, OS∅,
5407- ASA,    Low-dose aspirin reduces the risk of colorectal cancer recurrence in patients with resected PI3K-altered localised disease, according to the ALASCCA trial.
- Trial, CRC, NA
Dose↝, Risk↓,
5793- ASA,    Aspirin Recapitulates Features of Caloric Restriction
- in-vitro, Nor, NA
*CRM↑, *HATs↓, *NF-kB↓, *EP300↓,
1304- ASA,    Aspirin Inhibits Colorectal Cancer via the TIGIT-BCL2-BAX pathway in T Cells
- in-vitro, CRC, NA - in-vivo, NA, NA
TumCP↓, Apoptosis↑, Bcl-2↓, BAX↑, IL10↓, LTA/TNF-β↓,
1028- ASA,    Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
- vitro+vivo, Ovarian, NA
TumCP↓, TumW↓, PD-L1↓, Ki-67↓, H3K27ac∅, eff↑,
1096- ASA,    Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review)
- Review, NA, NA
TumMeta↓, COX1↓, CTC↓,
1142- Ash,    Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer
- Review, BC, MCF7 - NA, BC, MDA-MB-231 - NA, Nor, HMEC
Apoptosis↑, ROS↑, DNAdam↑, OXPHOS↓, *ROS∅, Bcl-2↓, XIAP↓, survivin↓, DR5↑, IKKα↓, NF-kB↓, selectivity↑, *ROS∅, eff↓, Paraptosis↑,
5393- Ash,    Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP
- in-vivo, Nor, NA
*BioAv↝, *other↝, *Half-Life↓,

Showing Research Papers: 901 to 950 of 8263
Prev Page 19 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8263

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↑, 2,   GPx4↓, 1,   GSH↓, 1,   HO-1↓, 2,   Iron↓, 1,   Keap1↓, 1,   NRF2↓, 1,   NRF2∅, 1,   OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 9,  

Metal & Cofactor Biology(tgid=2) ⓘ

TfR1/CD71↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 3,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 2,   ECAR↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 3,   HK2↓, 1,   lactateProd↓, 2,   LDH↓, 1,   LDHA↓, 2,   PKM2↓, 5,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 3,   Apoptosis↓, 1,   Apoptosis↑, 8,   BAX↑, 3,   Bcl-2↓, 4,   Casp12↑, 1,   Casp3↑, 5,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 2,   DR5↑, 1,   Ferroptosis↑, 2,   Mcl-1↓, 1,   MOMP↑, 1,   necrosis↑, 1,   Paraptosis↑, 1,   Pyro↑, 1,   survivin↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 4,   other↑, 2,   other↝, 6,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   eIF2α↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   DNArepair↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 1,   EMT↓, 2,   H3K27ac∅, 1,   mTOR↓, 1,   PI3K↓, 2,   TumCG↓, 3,  

Migration(tgid=13) ⓘ

AntiAg↑, 2,   E-cadherin↑, 1,   Ki-67↓, 1,   KRAS↓, 1,   MMP2↓, 2,   MMP9↓, 1,   Slug↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP↓, 5,   TumMeta↓, 6,   Twist↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   TXA2↓, 2,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 6,   IKKα↓, 1,   IL10↓, 1,   Imm↑, 1,   Inflam↓, 1,   LTA/TNF-β↓, 1,   NF-kB↓, 2,   PD-L1↓, 2,   PGE2↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 5,   Dose↑, 1,   Dose↝, 5,   eff↓, 5,   eff↑, 12,   RadioS↑, 1,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

CTC↓, 1,   Ki-67↓, 1,   KRAS↓, 1,   LDH↓, 1,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 2,   hepatoP↝, 1,   OS∅, 2,   Risk↓, 14,   Risk↑, 2,   Risk↝, 1,   Risk∅, 2,   toxicity↓, 1,   TumW↓, 1,  
Total Targets: 113

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Ferroptosis↓, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 1,   ROS∅, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CRM↑, 1,  

Cell Death(tgid=5) ⓘ

Ferroptosis↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↓, 1,   other↑, 1,   other↝, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EP300↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↓, 1,   AntiAg↑, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

TXA2↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 6,   COX2/PTGS2↓, 3,   Inflam↓, 3,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 2,   Dose↝, 1,   Half-Life↓, 6,   Half-Life↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

GutMicro↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 4,   toxicity↓, 2,  
Total Targets: 27

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page